- Home
- SYBT vs VERA Comparison
SYBT vs VERA Comparison
Compare SYBT & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYBT
- VERA
- Stock Information
- Founded
- SYBT 1904
- VERA 2016
- Country
- SYBT United States
- VERA United States
- Employees
- SYBT N/A
- VERA N/A
- Industry
- SYBT Major Banks
- VERA Biotechnology: Pharmaceutical Preparations
- Sector
- SYBT Finance
- VERA Health Care
- Exchange
- SYBT Nasdaq
- VERA Nasdaq
- Market Cap
- SYBT 2.2B
- VERA 2.0B
- IPO Year
- SYBT N/A
- VERA 2021
- Fundamental
- Price
- SYBT $83.01
- VERA $24.00
- Analyst Decision
- SYBT Hold
- VERA Buy
- Analyst Count
- SYBT 3
- VERA 8
- Target Price
- SYBT $80.33
- VERA $64.63
- AVG Volume (30 Days)
- SYBT 149.7K
- VERA 2.3M
- Earning Date
- SYBT 07-23-2025
- VERA 08-07-2025
- Dividend Yield
- SYBT 1.49%
- VERA N/A
- EPS Growth
- SYBT 16.29
- VERA N/A
- EPS
- SYBT 4.14
- VERA N/A
- Revenue
- SYBT $353,277,000.00
- VERA N/A
- Revenue This Year
- SYBT $14.39
- VERA N/A
- Revenue Next Year
- SYBT $5.04
- VERA N/A
- P/E Ratio
- SYBT $20.05
- VERA N/A
- Revenue Growth
- SYBT 8.97
- VERA N/A
- 52 Week Low
- SYBT $47.96
- VERA $18.53
- 52 Week High
- SYBT $83.55
- VERA $51.61
- Technical
- Relative Strength Index (RSI)
- SYBT 74.50
- VERA 54.33
- Support Level
- SYBT $78.24
- VERA $22.76
- Resistance Level
- SYBT $81.97
- VERA $23.97
- Average True Range (ATR)
- SYBT 1.99
- VERA 1.21
- MACD
- SYBT 0.67
- VERA 0.15
- Stochastic Oscillator
- SYBT 95.00
- VERA 73.63
About SYBT Stock Yards Bancorp Inc.
Stock Yards Bancorp Inc operates as a bank. The bank has two reportable operating segments namely Commercial Banking and Wealth Management and Trust. Its services include loan and deposit services, cash management services, securities brokerage activities, mortgage origination, and others. It generates the majority of its revenue from the Commercial Banking segment.
About VERA Vera Therapeutics Inc.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.